Pathfinder Wealth Consulting’s Pfizer PFE Stock Holding History

Pathfinder Wealth Consulting’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,980	Closed	-$449K	–	115
2026 Q1	$449K	Sell	15,980 -2,165	-12%	-$57.6K	0.29%	83
2025 Q4	$452K	Buy	+18,145	New	+$458K	0.29%	82

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pathfinder Wealth Consulting's PFE Position: Q2 2026 in Review

Pathfinder Wealth Consulting sold out of Pfizer (PFE) in Q2 2026, closing a stake of 15,980 shares — an estimated $449K sold.

Pathfinder Wealth Consulting first reported a position in PFE in Q4 2025 and held it in 2 quarters. The position peaked at $452K in Q4 2025. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Pathfinder Wealth Consulting reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Pathfinder Wealth Consulting sold 15,980 Pfizer shares in Q2 2026, an estimated $449K.
Pathfinder Wealth Consulting first reported a position in Pfizer in Q4 2025 and held it in 2 quarters.
Pathfinder Wealth Consulting's Pfizer position peaked at $452K in Q4 2025.
2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Pathfinder Wealth Consulting's 13F filing for Q2 2026.